Skip to content

Released Nov 12, 2025, after the close

10-Q filed Nov 12, 2025, 43 days after period end · 0001390478-25-000020

Q3 2025 · 10-Q
Revenue$0.00derivedno prior Q3 2024 on fileno prior Q2 2025 on file
Net Income-$6.79MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.06N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$7,083,000N/M
Operating Cash Flowderived-$7,068,000N/M

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$0.00—$0.00$0.00
Net Income-$6.79M-$7.11M-$9.27M-$7.02M
EPS Diluted-$0.06-$0.10-$0.33-$0.34

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR